PARTNER 3 at 5 Years: Low-Risk Patients and TAVI… Quo Vadimus?
Five-year results from the PARTNER 3 trial, which evaluated the balloon-expandable SAPIEN 3® TAVI versus surgical aortic valve replacement (SAVR) in low-risk patients.
Your reference portal for Cardiovascular and Endovascular Surgery.
Previous
Next
If you wish to receive our monthly newsletter, containing all the news collected on our portal, please fill in your email address and click on the “Subscribe” button.